Valeant Pharmaceuticals has major plans for 2014, including the goal of becoming one of the world’s five-largest pharmaceutical companies. That goal, reports say, includes reaching a market value of more than $150 billion.
Valeant, based in Canada, has upped its market value from less than $3 billion in 2010 to its current value of $44 billion through major acquisitions.
Now, plans to merge with Actavis could now add yet another boost to its market value this year. Industry experts also note that a deal with Teva Pharmaceuticals could push Valeant in the right direction.
According to the head of healthcare research at Aegis Capital, Valeant’s $150 billion goal “is actually not unrealistic at all.”
”This transaction is going to happen in 2014, and it’s going to be a biggie,” he said.
Full Content: Businessweek
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Apple Faces Contempt Hearings Over App Store Reforms
May 19, 2024 by
CPI
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI